micro-community-banner
 
  • Saved

2yr
Empagliflozin Improves Cardiac Energetics During Ischaemia/Reperfusion by Directly Increasing Cardiac Ketone Utilisation

Empagliflozin Improves Cardiac Energetics During Ischaemia/Reperfusion by Directly Increasing Cardiac Ketone Utilisation

Source : https://pubmed.ncbi.nlm.nih.gov/37819017/

Heart failure remains a huge clinical burden. Clinical trials of SGLT2 inhibitors in patients with diabetes and heart failure have reported significant cardio-protection from EMPA treatment that appears independent of...

EMPA causes a switch in metabolism away from glucose oxidation toward increased ketone utilisation in the rat heart, thereby improving function and energetics both during ischaemia and recovery during reperfusion. This preference of ketone utilisation over glucose was observed under conditions of constant supply of substrate, suggesting that...

  • Saved

2yr
Evaluation of the Safety of Inpatient Empagliflozin in a Real-World Setting

Evaluation of the Safety of Inpatient Empagliflozin in a Real-World Setting

Source : https://pubmed.ncbi.nlm.nih.gov/37829225/

This real-world study of empagliflozin use in the inpatient setting found no significant differences in safety endpoints between empagliflozin and other oral antihyperglycemic agents. Larger-scale studies need to be performed...

This real-world study of empagliflozin use in the inpatient setting found no significant differences in safety endpoints between empagliflozin and other oral antihyperglycemic agents. Larger-scale studies need to be performed before the use of empagliflozin can be routinely recommended in the inpatient setting.

  • Saved

2yr
Coverage of the Heart Failure Society of America Annual Scientific Meeting 2023

The 2023 annual scientific meeting of the Heart Failure Society of America (HFSA) is being held Oct. 6 to 9 at the Huntington Convention Center in Cleveland. The four-day program includes up-to-date science and translational research on diagnosing and treating all types of heart failure including heart failure with reduced ejection fraction (HFrEF).

Click above for a summary of some presentations that caught our eye at the conference.

  • Saved

2yr
Empagliflozin Suppresses the Differentiation/Maturation of Human Epicardial Preadipocytes and Improves Paracrine Secretome Profile

Empagliflozin Suppresses the Differentiation/Maturation of Human Epicardial Preadipocytes and Improves Paracrine Secretome Profile

Source : https://www.sciencedirect.com/science/article/pii/S2452302X23002280?via=ihub

Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce epicardial adipose tissue (EAT) in humans, enhancing cardioprotective effects on heart failur...

Empagliflozin suppresses human epicardial preadipocyte differentiation/maturation, likely inhibiting epicardial adipogenesis and improving the paracrine secretome profile of EAT, particularly by regulating IL6 expression.

  • Saved

2yr
The SGLT2 Inhibitor Empagliflozin Attenuates Atherosclerosis Progression by Inducing Autophagy

The SGLT2 Inhibitor Empagliflozin Attenuates Atherosclerosis Progression by Inducing Autophagy

Source : https://link.springer.com/article/10.1007/s13105-023-00974-0

Cardiovascular disease due to atherosclerosis is one of the leading causes of death worldwide; however, the underlying mechanism has yet to be defined. The sodium-dependent glucose transporter 2 inhibitor (SGLT2i)...

Empagliflozin activates autophagy through the AMPK signaling pathway to delay the evolution of atherosclerosis, indicating that it may represent a new and effective drug for the clinical treatment of atherosclerosis.